Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
Authors Yasui-Furukori N, Hashimoto K, Kubo K, Tomita T, Nakagami T
Received 17 December 2012
Accepted for publication 3 January 2013
Published 3 March 2013 Volume 2013:9 Pages 317—320
DOI https://doi.org/10.2147/NDT.S41738
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita
Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient's usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1.
Keywords: schizophrenia, antipsychotic, OROS, diarrhea, Positive and Negative Syndrome Scale
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.